Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy.

ABSTRACT:

Background

In situ tumor vaccine has been gradually becoming a hot research field for its advantage of achieving personalized tumor therapy without prior antigen identification. Various in situ tumor vaccine regimens have been reported to exert considerable antitumor efficacy in preclinical and clinical studies. However, the design of in situ tumor vaccines still needs further optimization and the underlying immune mechanism also waits for deeper investigation.

Methods

A novel triple in situ vaccine strategy that combining local radiation with intratumoral injection of TLR9 agonist CpG and OX40 agonist was established in this sturdy. Local and abscopal antitumor efficacy as well as survival benefit were evaluated in the bilateral tumors and pulmonary metastasis model of B16F

SUBMITTER: Sun Z 

PROVIDER: S-EPMC10498626 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature